Markus Warmuth, Monte Rosa Therapeutics CEO
October 28, 2024 07:00 AM EDT
Deals

No­var­tis pays Monte Rosa $150M for Phase 1 drug in lat­est en­dorse­ment of mol­e­c­u­lar glues

Max Bayer

Pharma Reporter

No­var­tis is get­ting a hold of one of Monte Rosa Ther­a­peu­tics’ clin­i­cal-stage mol­e­c­u­lar glues, and it’s putting more than $2.2 bil­lion on the ta­ble. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

For­mer Seagen CEO David Ep­stein to lead new biotech with VEGF bi­func­tion­al an­ti­body

Ab­b­Vie makes $1.4B ac­qui­si­tion of Alzheimer's biotech

Fog­Phar­ma re­brands as Para­bilis Med­i­cines, as CEO Math­ai Mam­men high­lights next drugs

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

Synaf­fix, in­dus­try's ADC part­ner of choice, spins out a start­up pipeline

Bio­gen's full Ph2 da­ta for IgA nephropa­thy drug; Sanofi in­vests in obe­si­ty biotech

A service from the Financial Times